[HTML][HTML] Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy …
…, A Hubalewska-Dydejczyk, R Mikołajczak… - European journal of …, 2011 - Springer
Purpose Peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin
analogues is a treatment option for patients with disseminated neuroendocrine tumours (NET). …
analogues is a treatment option for patients with disseminated neuroendocrine tumours (NET). …
[HTML][HTML] Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals
…, B Farstad, A Faivre-Chauvet, R Mikolajczak… - European journal of …, 2010 - Springer
This guidance is meant as a guidance to Part B of the EANM “Guidelines on Good Radiopharmacy
Practice (GRPP)” issued by the Radiopharmacy Committee of the EANM (see www.…
Practice (GRPP)” issued by the Radiopharmacy Committee of the EANM (see www.…
[HTML][HTML] Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma
A Sowa-Staszczak, D Pach, R Mikołajczak… - European journal of …, 2013 - Springer
Purpose The objective of this article is to present a new method for the diagnosis of insulinoma
with the use of [Lys 40 (Ahx-HYNIC- 99m Tc/EDDA)NH 2 ]-exendin-4. Methods Studies …
with the use of [Lys 40 (Ahx-HYNIC- 99m Tc/EDDA)NH 2 ]-exendin-4. Methods Studies …
Evaluation of [99mTc/EDDA/HYNIC0] octreotide derivatives compared with [111In-DOTA0, Tyr3, Thr8] octreotide and [111In-DTPA0] octreotide: does tumor or …
…, J Chen, P Powell, R Mikolajczak… - Journal of nuclear …, 2005 - Soc Nuclear Med
Radiolabeled somatostatin analogs are important tools for the in vivo localization and targeted
radionuclide therapy of somatostatin receptor–positive tumors. The aim of this study was …
radionuclide therapy of somatostatin receptor–positive tumors. The aim of this study was …
[HTML][HTML] 67Cu Production Capabilities: A Mini Review
…, G Pupillo, I Cieszykowska, CS Cutler, R Mikołajczak - Molecules, 2022 - mdpi.com
Is the 67 Cu production worldwide feasible for expanding preclinical and clinical studies?
How can we face the ingrowing demands of this emerging and promising theranostic …
How can we face the ingrowing demands of this emerging and promising theranostic …
[HTML][HTML] Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)
…, M Tomaszuk, M Kołodziej, R Mikołajczak… - European journal of …, 2011 - Springer
Purpose Neuroendocrine tumours (NET) are a heterogeneous group of neoplasms of diffuse
neuroendocrine cells. Surgery is the main aim in the treatment of NETs, which becomes …
neuroendocrine cells. Surgery is the main aim in the treatment of NETs, which becomes …
[HTML][HTML] Production of scandium radionuclides for theranostic applications: towards standardization of quality requirements
R Mikolajczak, S Huclier-Markai, C Alliot… - EJNMMI …, 2021 - Springer
In the frame of “precision medicine”, the scandium radionuclides have recently received
considerable interest, providing personalised adjustment of radiation characteristics to optimize …
considerable interest, providing personalised adjustment of radiation characteristics to optimize …
Long-term results and tolerability of tandem peptide receptor radionuclide therapy with 90Y/177Lu-DOTATATE in neuroendocrine tumors with respect to the primary …
…, D Pawlak, MI Bąk, B Kos-Kudła, R Mikołajczak… - Annals of Nuclear …, 2017 - Springer
Introduction The peptide receptor radionuclide therapy (PRRT) with 90 Y and 177 Lu is a
form of molecular targeted therapy for inoperable or disseminated neuroendocrine tumors (NET…
form of molecular targeted therapy for inoperable or disseminated neuroendocrine tumors (NET…
Radiometals for imaging and theranostics, current production, and future perspectives
R Mikolajczak, NP van der Meulen… - Journal of Labelled …, 2019 - Wiley Online Library
The aim of this review is to make the reader familiar with currently available radiometals, their
production modes, capacities, and quality concerns related to their medical use, as well as …
production modes, capacities, and quality concerns related to their medical use, as well as …
[HTML][HTML] Tandem peptide receptor radionuclide therapy using 90Y/177Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter …
…, P Gut, I Łoń, D Pawlak, R Mikołajczak… - European Journal of …, 2020 - Springer
Introduction One of the concepts of theranostics in nuclear medicine is peptide receptor
radionuclide therapy (PRRT), whereby labeled somatostatin analogs are used for imaging and …
radionuclide therapy (PRRT), whereby labeled somatostatin analogs are used for imaging and …